Free Trial
NASDAQ:CSCI

COSCIENS Biopharma (CSCI) Stock Price, News & Analysis

COSCIENS Biopharma logo
$3.72 +0.12 (+3.19%)
As of 06/10/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About COSCIENS Biopharma Stock (NASDAQ:CSCI)

Key Stats

Today's Range
$3.54
$3.54
50-Day Range
$2.44
$3.82
52-Week Range
$1.96
$6.77
Volume
290 shs
Average Volume
11,957 shs
Market Capitalization
$11.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Receive CSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CSCI Stock News Headlines

CSCI COSCIENS Biopharma Inc.
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More Headlines

CSCI Stock Analysis - Frequently Asked Questions

COSCIENS Biopharma's stock was trading at $2.77 on January 1st, 2025. Since then, CSCI stock has increased by 34.4% and is now trading at $3.7240.
View the best growth stocks for 2025 here
.

COSCIENS Biopharma Inc. (NASDAQ:CSCI) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.16) earnings per share for the quarter. The business had revenue of $1.50 million for the quarter. COSCIENS Biopharma had a negative trailing twelve-month return on equity of 95.93% and a negative net margin of 428.43%.

Shares of CSCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

Last Earnings
5/13/2025
Today
6/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CSCI
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.55 million
Net Margins
-428.43%
Pretax Margin
-547.63%

Debt

Sales & Book Value

Annual Sales
$9.03 million
Price / Cash Flow
N/A
Book Value
$14.99 per share
Price / Book
0.25

Miscellaneous

Free Float
3,772,000
Market Cap
$11.72 million
Optionable
N/A
Beta
0.74
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:CSCI) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners